The less immune inflamed IS may be eligible to treatments that convert a cold immune landscape into a hot immune landscape, such as radiotherapy and chemotherapy, or novel treatment options as oncolytic viruses, cancer vaccines or combinations with TGF‐β inhibitors. Here, TGFB1 is linked to cancer.